Design Therapeutics, Inc. (DSGN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$9.67-9.03%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · DSGN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-11-05 · Compared with 116 industry peers · Company calendar date is not available
DSGN — litigation filed
Dated 2026-05-18
Other Events. On May 18, 2026, Design Therapeutics, Inc. (the “Company”) announced biomarker and clinical data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich ataxia (“FA”). RESTORE-FA Key Data Highlights RESTORE-FA is a Phase 1/2 clinical trial evaluating DT-216P2 in patients with FA, designed to assess safety, pharmacokinetics, pharmacodynamics, and exploratory clinical endpoints. As of May 17, 2026, 16 patients had completed treatment with weekly…
Why it matters: The company had $207.4 million in cash and securities at June 2026. More cash use could shorten the time available for its trials.
Worry ifA later report keeps cash and securities near or above $200 million and still states runway into 2029.
Less concerning ifA later report shows cash below $200 million or says the planned runway no longer reaches 2029.
Why it matters: The delayed study update will test safety and cornea markers in FECD patients. On-time data would keep this program moving.
Watch forThe company reports DT-168 Phase 2 data in 2027, with safety and cornea marker results from the planned trial.
Also watch forThe data slip beyond 2027, or the company reports that eye-drop supply still blocks the trial.
Why it matters: This update will show how the company plans to move DT-216P2 toward later trials. A clear plan would support the Friedreich ataxia program.
Supportive ifBy the end of Q4 2026, the company shares a registrational plan for DT-216P2 and keeps 12-week data on track for Q1 2027.
Worry ifThe company delays its registrational update past Q4 2026 or pushes the 12-week data past Q1 2027.
Why it matters: The 12-week results test whether the early rise in frataxin lasts with longer dosing. This is a key test of DT-216P2.
Watch forQ1 2027 data show higher blood FXN protein from baseline after 12 weeks, with a dose response and no new safety issue.
Also watch forQ1 2027 data show no rise in blood FXN protein, no dose response, or a new safety issue; or the data are delayed.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$226 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $675 loss on $10,000 · 6.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,934 loss on $10,000 · 39.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.